Haptoglobin polymorphism and peripheral arterial occlusive disease

被引:61
|
作者
Delanghe, J
Langlois, M
Duprez, D
De Buyzere, M
Clement, D
机构
[1] State Univ Ghent Hosp, Dept Clin Chem, B-9000 Ghent, Belgium
[2] Belgian Natl Fund Sci Res, Flanders, Belgium
[3] State Univ Ghent Hosp, Dept Cardiol, B-9000 Ghent, Belgium
关键词
peripheral arterial occlusive disease; atherosclerosis; haptoglobin polymorphism; treadmill testing; angiogenesis;
D O I
10.1016/S0021-9150(99)00079-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Haptoglobin (Hp) 2-2 phenotype is a genetic risk factor in coronary atherosclerosis. In this study, haptoglobin phenotypes were determined in 141 patients with peripheral arterial occlusive disease (PAOD) and compared to a reference population (n = 1000). The relative Hpl allele frequency was decreased among PAOD patients (0.294 vs. 0.403 for the reference population, P < 0.01) due to an overrepresentation of the Hp 2-2 phenotype (50%, odds ratio 1.82(95% C.I. 1.28-2.60), P < 0.001). This finding was even more pronounced in non-diabetic and in non-smoking PAOD patients (Hpl allele frequencies: 0.265 and 0.228, respectively). Serum lipids, inflammatory parameters, and blood pressure levels were comparable among the Hp phenotypes, but serum levels of the antioxidant vitamin C were lower in Hp 2-2 patients than in patients with another phenotype (P < 0.05). In PAOD patients with severe atherosclerotic lesions, maximal walking distance of patients carrying a Hp 2-2 phenotype (225-525 m) exceeded that of other Hp phenotypes (50-242 m) (interquartile ranges) (P < 0.05). The findings demonstrate that, despite an increased risk for developing PAOD, the Hp 2-2 phenotype is associated with a longer maximal walking distance which might be attributed to the earlier reported in vitro angiogenic properties of the Hp 2-2 molecule. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:287 / 292
页数:6
相关论文
共 50 条
  • [1] Angiotensin-converting enzyme gene insertion/deletion polymorphism and peripheral arterial occlusive disease
    Taute, BM
    Handschug, K
    Taute, R
    Seifert, H
    Glaser, C
    Podhaisky, H
    VASA-JOURNAL OF VASCULAR DISEASES, 1998, 27 (03): : 149 - 153
  • [2] Screening for peripheral occlusive arterial disease
    Diehm, C.
    Lawall, H.
    Pittrow, D.
    GEFASSCHIRURGIE, 2009, 14 (05): : 370 - +
  • [3] Thrombophilias and peripheral arterial occlusive disease
    Le Hello, C.
    Blacher, J.
    Conard, J.
    Piette, J. -C.
    Constans, J.
    JOURNAL DES MALADIES VASCULAIRES, 2008, 33 (03) : 126 - 136
  • [4] Autoantibodies and peripheral arterial occlusive disease
    Kroeger, K
    Kreuzfelder, E
    HERZ, 2004, 29 (01) : 26 - 31
  • [5] Upuate peripheral arterial occlusive disease
    Blessing, E.
    HERZ, 2015, 40 (07) : 1013 - 1022
  • [6] CT Angiography of Peripheral Arterial Occlusive Disease
    Chin, Anne S.
    Rubin, Geoffrey D.
    TECHNIQUES IN VASCULAR AND INTERVENTIONAL RADIOLOGY, 2006, 9 (04) : 143 - 149
  • [7] PROSTANOIDS IN THERAPY OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
    CREUTZIG, A
    CASPARY, L
    THERAPIE, 1991, 46 (03): : 241 - 245
  • [8] HEMODILUTION IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
    KIESEWETTER, H
    JUNG, F
    ERDLENBRUCH, W
    WENZEL, E
    INTERNATIONAL ANGIOLOGY, 1992, 11 (03) : 169 - 175
  • [9] Bilaterality and symmetry of peripheral arterial occlusive disease
    Müller-Bühl, U
    Klimm, HD
    PERFUSION, 2003, 16 (03): : 100 - 104
  • [10] Lack of an association between angiotensin converting enzyme gene polymorphism and peripheral arterial occlusive disease
    Karagiannis, A
    Balaska, K
    Tziomalos, K
    Gerasimidis, T
    Karamanos, D
    Papayeoryiou, A
    Zamboulis, C
    VASCULAR MEDICINE, 2004, 9 (03) : 189 - 192